Last reviewed · How we verify

Enaroy — Competitive Intelligence Brief

Enaroy (ENARODUSTAT) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Hematology.

marketed Egl nine homolog 1 Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Enaroy (ENARODUSTAT) — Japan Tabacco.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enaroy TARGET ENARODUSTAT Japan Tabacco marketed Egl nine homolog 1
Jesduvroq DAPRODUSTAT GSK marketed Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] Egl nine homolog 1 2023-01-01
Allomaleic Acid FUMARIC ACID marketed Vitamin C [EPC] Egl nine homolog 1
Musredo MOLIDUSTAT BAYER YAKUHIN, Ltd marketed Egl nine homolog 1
Butanedioic Acid SUCCINIC ACID marketed Vitamin C [EPC] Egl nine homolog 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enaroy — Competitive Intelligence Brief. https://druglandscape.com/ci/enarodustat. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: